CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences (NASDAQ:HLCS), a life science company focused on innovative genetic analysis technologies, announced today that it has entered into a scientific collaboration with the Children’s Oncology Group (COG) in order to interrogate a wide spectrum of genomic variation within various sarcomas, an aggressive type of bone or soft tissue cancer usually found in children and young adults. New insight into molecular events occurring in primary and metastatic tumor states is critically important to identify new potential therapeutic targets and further improve patient outcomes.
